Torren Management’s Cue Biopharma CUE Stock Holding History

Torren Management’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11	Closed	-$99	–	1113
2025 Q4	$99	Buy	+11	New	+$202	﹤0.01%	1418

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Geode Capital Management

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return

Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return

Torren Management's CUE Position: Q1 2026 in Review

Torren Management sold out of Cue Biopharma (CUE) in Q1 2026, closing a stake of 11 shares — an estimated $99 sold.

Torren Management first reported a position in CUE in Q4 2025 and held it in 1 quarter. The position peaked at $99 in Q4 2025. 55 funds tracked by Wall St. Rank hold CUE as of Q1 2026.

Torren Management reported no remaining Cue Biopharma position as of Q1 2026 after selling out during the quarter.
Torren Management sold 11 Cue Biopharma shares in Q1 2026, an estimated $99.
Torren Management first reported a position in Cue Biopharma in Q4 2025 and held it in 1 quarter.
Torren Management's Cue Biopharma position peaked at $99 in Q4 2025.
55 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.